Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9852W HIGH $9.50
Volume
16.92 K
Value Traded
52.07 K
Short % Float
1.35%
-8.83%Week
+4.78%1 Month
+13.96%3 Month
+50.64%6 Month
-63.75%5 Year
-63.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
41.12 M
EPS (TTM)
-0.19
P/E Ratio
-
Ent. Value
23.65 M
Total Shares
11.71 M
Float Shares
5.95 M
Insiders
49.21%
Institutions
18.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NSRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Nasus Pharma Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nasus Pharma Ltd.
52Total events
6Upcoming
10Tier-1 (high impact)
2025 to 2027Coverage
Upcoming catalysts 2
Event history 35
▲First Patient DosedNS003Trial
First patient enrolled and dosed in Phase 1 PK trial of NS003
chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV)source ↗
▲IND ClearanceNS002IND
FDA clears IND for NS002 intranasal epinephrine in anaphylaxis
anaphylaxissource ↗
▲Preclinical PoCNS003Preclinical
NS003 preclinical PK study positive results announced
chemotherapy induced and post-operative nausea and vomitingsource ↗
◆First Patient DosedNS003Trial
First-in-human PK study of NS003 to initiate
chemotherapy and post-operative nausea and vomitingsource ↗
◆Oral PresentationPresentation
Nasus Pharma management to present at Zacks Life Sciences Investor Forum
◆Oral PresentationNS002Presentation
Virtual KOL event to discuss NS002 for anaphylaxis
anaphylaxissource ↗
▲Preclinical PoCNS003Preclinical
Positive results from preclinical PK and safety study of NS003
chemotherapy and post-operative nausea and vomitingsource ↗
▲Topline ReadoutNS002Clinical Data
Phase 2 topline results for NS002 demonstrate statistically significant improvements in early absorption vs EpiPen
Anaphylaxissource ↗
◆Oral PresentationNS002Presentation
Topline analysis presentation of NS002 Phase 2 repeated dose study
anaphylaxissource ↗
▲Topline ReadoutNS002Clinical Data
Positive top line data from Phase 2 study of NS002
anaphylaxissource ↗
◆Oral PresentationPresentation
Nasus Pharma management to present at Life Sciences Investor Forum
◆Quarterly UpdateCorporate
Special General Meeting of Shareholders to vote on capital increase and equity compensation
◆Poster PresentationNS002Presentation
Nasal epinephrine spray for anaphylaxis: which is better - powder or liquid? Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid nasal spray which could lead to enhanced blood absorption
anaphylaxissource ↗
▼Equity OfferingCorporate
Closing of $15.0 million private placement of ordinary shares and warrants
▲Partnership / LicenseNS002Corporate
Expanded agreement with Aptar for NS002 development and commercialization
anaphylaxissource ↗
▲Partnership / LicenseNS002Corporate
Expanded collaboration agreements with Aptar France S.A.S. and AptarGroup Inc.
anaphylaxissource ↗
▲IND ClearanceNS002IND
Received authorization from Health Canada to initiate Phase 2 study
anaphylaxissource ↗
▲First Patient DosedNS002Trial
Dosed first patient in Phase 2 open-label trial comparing NS002 to EpiPen
anaphylaxissource ↗
●IpoCorporate
Closing of initial public offering of 1,250,000 ordinary shares at $8.00 per share, gross proceeds $10 million
▲Oral PresentationNS002Presentation
Presented integrated data from two early clinical trials of NS002
anaphylaxissource ↗
Past FDA Catalysts and PDUFA Decisions
How NSRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | NS002 (intranasal epinephrine powder formulation) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$17M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 71%
Micro Cap(rank 469 of 660)
Percentile Rank
Nasus Pharma Ltd. faces pipeline headwinds (29/100), with $580M risk-adjusted pipeline value, led by Epinephrine in Anaphylaxis Food (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Epinephrine Small moleculeNCT07045701 | Anaphylaxis Food | Phase 2 | ENROLLING BY_INVITATION | 30 | Jul 12, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NSRX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Teleman Dan BenjaminDirector, Officer (Chief Executive Officer) | Buy | 6,550 163,541 held | $3.10 | 06/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NSRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NSRX for Q2 2026. | ||||
NSRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NSRX ranks across every disease it competes in
Competitive Position is a premium feature
See how NSRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNSRX News
NSRXNasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma has successfully enrolled and dosed the first patient in its Phase 1 trial for NS003, an intranasal formulation of ondansetron. The trial aims to evaluate the pharmacokinetics and safety of NS003, which has shown promising results in pre-clinical studies. The company anticipates releasing topline data before the end of the year.
Read more →NSRX▲ +7.2%on this news
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Nasus Pharma has received FDA clearance for its IND application for NS002, an intranasal epinephrine powder aimed at treating anaphylaxis. The company plans to initiate a pivotal study in Q4 2026, with topline data expected in Q1 2027. This development could provide a needle-free alternative for patients reliant on injectors like EpiPen.
Read more →NSRXNasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Nasus Pharma Ltd. will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York. The company's management will present and engage in one-on-one meetings with investors. Their lead product candidate, NS002, is an intranasal treatment for allergic reactions, highlighting their innovative approach in biopharmaceuticals.
Read more →NSRX▲ +5.2%on this news
Nasus Pharma Announces Transition of Chief Financial Officer
Nasus Pharma announced the departure of Chief Financial Officer Eyal Rubin, who will leave the company on September 18, 2026, to pursue a new opportunity. Oren Elmaliach, the current Director of Finance, has been appointed as the Interim CFO. The leadership expressed gratitude for Rubin's contributions and confidence in Elmaliach's ability to maintain continuity during the transition.
Read more →NSRXNasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Nasus Pharma Ltd. reported its financial results for the first half of 2026, highlighting progress in its clinical programs, particularly for NS002 and NS003. The company appointed Brendan O’Grady as CEO and is on track to initiate pivotal studies for NS002 in anaphylaxis treatment. Despite a net loss increase, cash reserves improved significantly due to a private placement.
Read more →NSRXNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Nasus Pharma has appointed Brendan P. O'Grady as its new CEO, effective July 27, 2026. O'Grady will focus on advancing the company's lead product, NS002, towards a pivotal trial and enhancing its business development initiatives. His extensive experience in the pharmaceutical industry is expected to drive strategic growth and maximize the value of Nasus's proprietary technology.
Read more →NSRXNasus Pharma to Participate in the Zacks Life Sciences Investor Forum
Nasus Pharma Ltd. will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live presentations and interactive Q&A sessions for investors. The company focuses on developing intranasal products, including a needle-free epinephrine alternative for anaphylaxis. A replay of the presentation will be available post-event.
Read more →NSRXNasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma announced positive results from a preclinical study of NS003, an intranasal formulation of ondansetron. The study demonstrated a pharmacokinetic profile comparable to intravenous ondansetron, with a favorable safety profile. The company plans to initiate a first-in-human PK study in Q3 2026, aiming to address unmet needs in nausea management for chemotherapy patients.
Read more →NSRXNasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
Nasus Pharma will host a virtual KOL event on June 10, 2026, to discuss NS002, its intranasal epinephrine candidate for anaphylaxis. Experts will review Phase 2 data showing NS002's advantages over traditional EpiPen® injections. The event aims to address the unmet needs in anaphylaxis treatment, especially for pediatric patients.
Read more →NSRXNasus Pharma to Participate in May 2026 Investor Conferences
Nasus Pharma Ltd. has announced its participation in upcoming investor conferences in May 2026. CFO Eyal Rubin will engage in one-on-one meetings at the Market Movers Investor Summit and the D. Boral Capital Global Conference, both held in New York. The company focuses on developing innovative intranasal products, including a needle-free alternative for anaphylaxis treatment.
Read more →NSRXNasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma Ltd. announced its participation in two upcoming investor conferences in New York. CFO Eyal Rubin will engage in 1x1 meetings at both the Market Movers Investor Summit on May 5 and the D. Boral Capital Global Conference on May 7. The company focuses on developing innovative intranasal products, including a needle-free alternative for anaphylaxis treatment.
Read more →NSRX▲ +10.8%on this news
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma has reported positive topline results from its Phase 2 study of NS002, indicating its potential as a best-in-class epinephrine delivery system. The company plans to initiate a pivotal study for NS002 in Q4 2026, with a readout expected in Q1 2027. Additionally, Nasus is advancing its pipeline with other intranasal products targeting nausea, metabolic disorders, and cardiovascular diseases, all set for first-in-human studies in 2026.
Read more →NSRX▼ -38%on this news· ran to -50% by day 3
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold
Nasus Pharma has announced positive results from a Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation aimed at treating anaphylaxis. The study showed NS002 achieved a significantly faster delivery of epinephrine compared to EpiPen, with 88.4% of subjects reaching the therapeutic threshold at 5 minutes. Additionally, NS002 exhibited a favorable safety profile with no serious adverse events. The company is set to initiate a pivotal clinical study for NS002 in the fourth quarter of 2026, seeking to provide a needle-free alternative for patients experiencing anaphylaxis.
Read more →NSRX▼ -15.4%on this news
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Nasus Pharma announced a conference call on March 16, 2026, to present topline analysis from its Phase 2 clinical study of NS002, an intranasal epinephrine powder. The call will include a data presentation followed by a Q&A session. NS002 is being developed as a needle-free alternative for treating anaphylaxis.
Read more →NSRX▼ -15.4%on this newsshared move
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Nasus Pharma Ltd. will present at the Life Sciences Investor Forum on March 11, 2026. CEO Dan Teleman will lead the presentation, highlighting the company's focus on intranasal products for emergency medical conditions. The forum will also offer opportunities for one-on-one meetings with management.
Read more →NSRXTHE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Nasus Pharma Ltd. Preliminary 1. Definitions; Interpretation . (a) In these Articles, the following terms (whether or no
The article presents the amended and restated Articles of Association for Nasus Pharma Ltd., a limited liability company governed under the Israeli Companies Law. It defines key terms and establishes the framework for the company's governance, objectives, and capital structure. The Articles outline the rights of shareholders, the powers of directors, and provisions for meetings and resolutions, ensuring compliance with relevant laws and regulations. Overall, the document serves as a comprehensive guide for the company's operational framework.
Read more →NSRXNasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Nasus Pharma announced that it will present data on NS002, an investigational intranasal epinephrine powder, at the AAAAI 2026 Annual Meeting. The company emphasizes the product's potential for rapid absorption and stability, positioning it as a novel, needle-free alternative for treating anaphylaxis. The presentation will take place from February 27 to March 2 in Philadelphia.
Read more →NSRX▲ +5.4%on this newsshared move
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Nasus Pharma has successfully closed a $15 million private placement of ordinary shares and warrants. The funds will be used to advance their NS002 intranasal epinephrine product towards a pivotal study and NDA submission. The financing is expected to enhance the company's balance sheet and support ongoing development activities.
Read more →NSRXNasus Pharma Announces Pricing of $15.0 Million Private Placement
Nasus Pharma Ltd. has announced a private placement of ordinary shares and warrants, raising approximately $15 million. The placement involves both new and existing investors and is expected to close around February 12, 2026. Proceeds will be utilized to advance the clinical development of NS002 and initiate studies for other products in the pipeline.
Read more →About Nasus Pharma Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next NSRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime